Eli Lilly ·
In April 2025 Eli Lilly filed suit against Hims & Hers Health in the US District Court for the Southern District of New York, alleging that Hims' marketing of compounded tirzepatide constituted false advertising and unfair competition. The complaint focused on Hims' representation that its compounded tirzepatide was therapeutically equivalent to branded Mounjaro and Zepbound, which Lilly argued misled consumers. Hims moved to dismiss on multiple grounds, including that its statements were substantially true and that FDA primary jurisdiction should apply. The court denied the motion to dismiss in October 2025, setting the case for expedited discovery. The litigation continues through 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.